Glycorex Transplantation Ab Class B · NGM:GTAB.B
Glycorex Transplantation Ab Class B — Redeye Growth Day 2021
13 slides from Glycorex Transplantation Ab Class B's conference presentation, Jun 2, 2021
Slide 1: Redeye Growth Day June 2, 2021
Redeye Growth Day June 2, 2021 Pontus Nobréus CEO
Slide 2: Global burden of kidney failure – large impact on the individual and society
Global burden of kidney failure – large impact on the individual and society 14.5 million 9.7 million 5.4 million 2.6 million 2010 2030 ”Many developed countries spend 2–3% of their health care budgets on treatment for patients with ESKD, even though these Number of people receiving KRT patients com
Slide 3: Challenges with kidney transplantations
Challenges with kidney transplantations Gap between supply and demand ABO incompatible blood groups Kidney Paired Donation (KPD) O A B AB U.S. Government Information on Organ Donation and Transplantation (www.organdonor.gov) National Kidney Foundation
Slide 4: Glycosorb® ABO enables transplantations regardless of blood group
Glycosorb® ABO enables transplantations regardless of blood group
Slide 5: In clinical use since 2001 > 60 publications
In clinical use since 2001 > 60 publications • > 5,000 transplantations • ~ 30 countries • Living Donor Kidney transplantations performed with Glycosorb® ABO is estimated to save 700,000 dialysis treatments per year Glycosorb® ABO for transplantations of: • Kidney • Liver • Heart • Lung • Stem cells
Slide 6: Global transplantations by the numbers
Global transplantations by the numbers > 150,000 Transplantations 2019 ~ 98,000 Kidney Transplantations 2019 (Deceased and Living Donors) Lung Pancreas Heart 70 000 4% 6% 60 000 50 000 Liver 40 000 Kidney 23% 65% 30 000 20 000 10 000 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Deceased Donor
Slide 7: Glycosorb® ABO - large market potential Living Donor Kidney transplantations
Glycosorb® ABO - large market potential Living Donor Kidney transplantations EUROPE Turkey Mexico USA India ROW 0 2 000 4 000 6 000 8 000 10 000 12 000 Geographical distribution of number of Living Donor Kidney transplantations 2019 India, Mexico USA Europe & Turkey ~160 MSEK ~100 MSEK ~150 MSEK Liv
Slide 8: Increasing number of blood group incompatible transplantations with Glycosorb® ABO
Increasing number of blood group incompatible transplantations with Glycosorb® ABO Germany USA
Slide 9: Glycosorb® ABO – designed to enable access to universal blood plasma
Glycosorb® ABO – designed to enable access to universal blood plasma Glycosorb® ABO makes it possible to: • Improve stock keeping and logistics for the blood bank • Reduce risk for transfusion mistakes and delays Estimated market for universal blood plasma in EU: • Provide access to adequate blood p
Slide 10: R&D Pipeline – focus on autoimmune diseases
R&D Pipeline – focus on autoimmune diseases Rheumatoid Arthritis (RA) Other projects • 5 million people in EU • Myasthenia Gravis (MG) • No cure – immunosuppressive and • Impact on muscle function anti-inflammatory drugs – up to 10% do not respond • Typically treated with plasma exchange • Potential
Slide 11: Financials
Financials 40 Net sales 2016-2020 (MSEK) 35 30 25 20 Quarter 1, 2021 15 • Net sales: 4.9 (7.7) MSEK 10 • Net income: -5.3 (0.3) MSEK 5 • Earnings per share: -0.07 (0.00) SEK 0 • Cash position: 44.7 (56.2) MSEK 2016 2017 2018 2019 2020 Net income 2016-2020 (MSEK) Positive sales development after weak
Slide 12: Company, Applications, Transplantations
Company Applications Short term Mid/long term Unique competence in Living Donor (LD) Kidney transplantations LD Kidney transplantations: biologically active • increased market penetration existing carbohydrates – markets development of Transplantations Sales in Europe, India, Mexico & Turkey • geogr
Slide 13: Thank you! Q&A
Thank you! Q&A